Abstracts tagged "clinical trials and Autoimmune Skin Disease"

Abstract Number: 2242 • ACR/ARP Annual Meeting 2019
Evaluating Important Change in Cutaneous Disease Activity as an Efficacy Measure for Clinical Trials in Dermatomyositis
Sarah Ahmed¹, Srita Chakka ², Rebecca Krain ³, Rui Feng ⁴ and Victoria Werth ⁵, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia, ⁵Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA
Background/Purpose: The FDA uses near or total clearance in cutaneous disease in inflammatory skin conditions as an endpoint in clinical trials. However, patients may experience…